AR054507A1 - Sistema transdermico de vareniclina - Google Patents
Sistema transdermico de vareniclinaInfo
- Publication number
- AR054507A1 AR054507A1 ARP060103197A ARP060103197A AR054507A1 AR 054507 A1 AR054507 A1 AR 054507A1 AR P060103197 A ARP060103197 A AR P060103197A AR P060103197 A ARP060103197 A AR P060103197A AR 054507 A1 AR054507 A1 AR 054507A1
- Authority
- AR
- Argentina
- Prior art keywords
- varenicline
- transdermic
- transdermic system
- pharmaceutically acceptable
- prodrug form
- Prior art date
Links
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 title abstract 2
- 229960004751 varenicline Drugs 0.000 title abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones transdérmicas que comprenden vareniclina o su forma salina o de profármaco farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70296105P | 2005-07-26 | 2005-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054507A1 true AR054507A1 (es) | 2007-06-27 |
Family
ID=37175751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103197A AR054507A1 (es) | 2005-07-26 | 2006-07-25 | Sistema transdermico de vareniclina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110086086A1 (es) |
| EP (1) | EP1909773B1 (es) |
| JP (1) | JP2007031436A (es) |
| KR (2) | KR20090125294A (es) |
| CN (2) | CN101862310A (es) |
| AR (1) | AR054507A1 (es) |
| AT (1) | ATE524168T1 (es) |
| AU (1) | AU2006273772A1 (es) |
| BR (1) | BRPI0614171A2 (es) |
| CA (1) | CA2616695C (es) |
| IL (1) | IL188268A0 (es) |
| MX (1) | MX2007016458A (es) |
| NZ (1) | NZ564685A (es) |
| RU (1) | RU2388461C2 (es) |
| TW (1) | TWI327472B (es) |
| WO (1) | WO2007012963A1 (es) |
| ZA (1) | ZA200800032B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007058504A1 (de) * | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR) |
| WO2009107477A1 (ja) * | 2008-02-27 | 2009-09-03 | 久光製薬株式会社 | 貼付製剤 |
| US9155725B2 (en) * | 2008-02-27 | 2015-10-13 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch and packaged product |
| EP2262780A4 (en) * | 2008-03-06 | 2012-01-25 | Reddys Lab Ltd Dr | TARTRATE OF VARENICLINE AMORPHOUS |
| EP2268639A2 (en) | 2008-05-22 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| JP2010285415A (ja) * | 2009-06-15 | 2010-12-24 | Hisamitsu Pharmaceut Co Inc | バレニクリン又は薬学的に許容されるバレニクリン酸付加塩を含有する経皮薬物送達システムの包装体 |
| RU2012102052A (ru) | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| CN102541332A (zh) * | 2010-12-30 | 2012-07-04 | 联咏科技股份有限公司 | 单击手势判断方法、触控感应控制芯片、触控及电脑系统 |
| US20130053668A1 (en) * | 2011-08-26 | 2013-02-28 | Compose Element Limited | Kit and method for detecting blood sugar |
| US20160199315A1 (en) * | 2013-08-23 | 2016-07-14 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| KR102771688B1 (ko) * | 2016-09-07 | 2025-02-20 | 에스케이케미칼 주식회사 | 바레니클린의 경피 투여를 위한 약학 제제 |
| GB2561333B (en) | 2017-02-17 | 2020-06-03 | Bo Soederpalm | Treatment of alcohol use disorder |
| US10912734B2 (en) | 2018-05-16 | 2021-02-09 | Cipla Limited | Depot formulation |
| CN111135087A (zh) * | 2020-01-09 | 2020-05-12 | 范小玲 | 一种溶剂型透皮贴的工业化制备方法 |
| WO2022140480A1 (en) * | 2020-12-23 | 2022-06-30 | GameChanger Patch Co. | Transdermal patches for hangover minimization and/or recovery, and/or sleep improvement |
| CN113116814A (zh) * | 2021-04-01 | 2021-07-16 | 江苏山信药业有限公司 | 一种伐尼克兰透皮溶液剂及其制备方法和其应用 |
| CN116370439A (zh) * | 2022-04-01 | 2023-07-04 | 江苏山信药业有限公司 | 一种伐尼克兰透皮贴剂及其制备方法和其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US219196A (en) * | 1879-09-02 | Improvement in bretzel-machines | ||
| US127531A (en) * | 1872-06-04 | Improvement in car-starters | ||
| US4910020A (en) * | 1988-10-21 | 1990-03-20 | Macrochem Corporation | Transdermal medicator |
| DE3910578A1 (de) * | 1989-03-29 | 1990-10-04 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| ATE132751T1 (de) * | 1988-10-27 | 1996-01-15 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| US5008110A (en) * | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| JPH11501282A (ja) * | 1993-09-10 | 1999-02-02 | サイトメッド、インコーポレイテッド | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 |
| US5552399A (en) * | 1994-11-02 | 1996-09-03 | Janssen Pharmaceutica N.V. | Substituted tetracyclic azepine derivatives |
| US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
| IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
| KR100576583B1 (ko) * | 1997-12-22 | 2006-05-04 | 알자 코포레이션 | 서방성 약물 송달 장치용 속도 조절막 |
| EP1117389A1 (en) * | 1998-09-08 | 2001-07-25 | TheraTech, Inc. | Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs |
| HRP20030910B1 (hr) * | 2001-05-14 | 2011-11-30 | Pfizer Products Inc. | Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva |
| US20030008892A1 (en) * | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| DE10141651B4 (de) * | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
| DE60209929T2 (de) * | 2001-11-29 | 2006-11-16 | Pfizer Products Inc., Groton | Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen |
| EP1448235B1 (en) * | 2001-11-30 | 2007-03-14 | Pfizer Products Inc. | Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| US6676961B1 (en) * | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
| EP1523334A2 (en) * | 2002-07-18 | 2005-04-20 | Cytos Biotechnology AG | Hapten-carrier conjugates and uses thereof |
| JP2008516942A (ja) * | 2004-10-15 | 2008-05-22 | ファイザー・プロダクツ・インク | バレニクリンの鼻腔内、バッカル、舌下および肺送達のための組成物および方法 |
| CA2575764A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| CA2593432A1 (en) * | 2005-01-07 | 2006-07-13 | Prizer Products Inc. | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
-
2006
- 2006-06-13 US US11/574,045 patent/US20110086086A1/en not_active Abandoned
- 2006-07-13 KR KR1020097024108A patent/KR20090125294A/ko not_active Ceased
- 2006-07-13 AT AT06779913T patent/ATE524168T1/de not_active IP Right Cessation
- 2006-07-13 KR KR1020087002048A patent/KR20080018278A/ko not_active Withdrawn
- 2006-07-13 BR BRPI0614171-4A patent/BRPI0614171A2/pt not_active IP Right Cessation
- 2006-07-13 RU RU2008101926/15A patent/RU2388461C2/ru not_active IP Right Cessation
- 2006-07-13 AU AU2006273772A patent/AU2006273772A1/en not_active Abandoned
- 2006-07-13 MX MX2007016458A patent/MX2007016458A/es active IP Right Grant
- 2006-07-13 WO PCT/IB2006/002081 patent/WO2007012963A1/en not_active Ceased
- 2006-07-13 CA CA2616695A patent/CA2616695C/en not_active Expired - Fee Related
- 2006-07-13 EP EP06779913A patent/EP1909773B1/en not_active Not-in-force
- 2006-07-13 CN CN201010115865A patent/CN101862310A/zh active Pending
- 2006-07-13 CN CNA2006800276994A patent/CN101232876A/zh active Pending
- 2006-07-13 NZ NZ564685A patent/NZ564685A/en not_active IP Right Cessation
- 2006-07-25 JP JP2006201490A patent/JP2007031436A/ja active Pending
- 2006-07-25 TW TW095127076A patent/TWI327472B/zh not_active IP Right Cessation
- 2006-07-25 AR ARP060103197A patent/AR054507A1/es not_active Application Discontinuation
-
2007
- 2007-12-19 IL IL188268A patent/IL188268A0/en unknown
-
2008
- 2008-01-02 ZA ZA200800032A patent/ZA200800032B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110086086A1 (en) | 2011-04-14 |
| IL188268A0 (en) | 2008-04-13 |
| ATE524168T1 (de) | 2011-09-15 |
| CA2616695C (en) | 2011-07-05 |
| NZ564685A (en) | 2010-10-29 |
| ZA200800032B (en) | 2009-09-30 |
| WO2007012963A1 (en) | 2007-02-01 |
| EP1909773B1 (en) | 2011-09-14 |
| CA2616695A1 (en) | 2007-02-01 |
| CN101862310A (zh) | 2010-10-20 |
| RU2008101926A (ru) | 2009-09-10 |
| TWI327472B (en) | 2010-07-21 |
| JP2007031436A (ja) | 2007-02-08 |
| EP1909773A1 (en) | 2008-04-16 |
| CN101232876A (zh) | 2008-07-30 |
| RU2388461C2 (ru) | 2010-05-10 |
| BRPI0614171A2 (pt) | 2011-03-15 |
| KR20090125294A (ko) | 2009-12-04 |
| TW200731974A (en) | 2007-09-01 |
| MX2007016458A (es) | 2008-03-07 |
| AU2006273772A1 (en) | 2007-02-01 |
| KR20080018278A (ko) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054507A1 (es) | Sistema transdermico de vareniclina | |
| CL2007002916A1 (es) | Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras. | |
| CL2008003188A1 (es) | Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met. | |
| CL2007002594A1 (es) | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . | |
| EA200802008A1 (ru) | Фармацевтические композиции | |
| BRPI0815170A2 (pt) | Composição farmacêutica que compreende um inibidor de sglt 2 | |
| CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| NO20084253L (no) | Tetrahydroisokinolinderivater for a forbedre hukommelsesfunksjon | |
| CL2008001003A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
| NO20091845L (no) | Macrocykliske peptider som hepatitt C virus-inhibitorer | |
| BRPI0815190A2 (pt) | Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo | |
| CL2008001983A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras. | |
| NO20091846L (no) | Makrocykliske peptider som hepatitt C virus- inhibitorer | |
| CL2007003232A1 (es) | Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas. | |
| BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| BRPI0713031B8 (pt) | composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| FI20065842A0 (fi) | Alipaineviemärijärjestelmä | |
| CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |